A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube
Hepatitis C

Kim Hunter shares her experience with hepatitis C.


Luz Lugo, MD, explains the importance of hepatitis C testing.
en español

How well does HCV treatment work for people with HIV?

Almost all of what we know about treating hepatitis C in people living with HIV comes from clinical trials exploring the safety and effectiveness of pegylated interferon plus ribavirin alone, with HCV protease inhibitors.

Unfortunately, we also know that pegylated interferon combined with ribavirin is less effective in coinfected people, compared with those living with hepatitis C but not HIV.

Responses to pegylated interferon/ribavirin treatment vary by HCV genotype: For HIV/HCV-coinfected people with HCV genotype 1, sustained virological response (SVR) rates in clinical trials ranged from 14 percent to 38 percent. For people with HCV genotypes 2 and 3, SVR rates in clinical trials have been between 44 percent and 73 percent.

Preliminary results from studies exploring the effectiveness of pegylated interferon and ribavirin plus either Incivek or Victrelis are available. According to these clinical trials, the addition of either protease inhibitor improves SVR rates by roughly 30 percent in people living with HIV and genotype 1 HCV.

HCV treatment is more likely to work for people with HIV when:
They have an RVR (HCV viral load is undetectable after four weeks of treatment).
They have a cEVR or pEVR (HCV is either undetectable or has dropped by at least 2 logs, which is 99 percent, by week 12). It is important for people to be evaluated after three months (12 weeks) on treatment. If their HCV viral load hasn’t dropped significantly, treatment is stopped since this indicates that they’re very unlikely to achieve a sustained response.
They have the IL-28B CC genotype.
They are given weight-based ribavirin, or at least 800 mg per day. However, ribavirin has a number of side effects, including low red and white blood cell counts, which appear to be worse in HIV-positive people. In turn, it can be challenging to remain on a high enough dose of ribavirin to push HCV viral load to undetectable—and to keep it there.
They properly manage the side effects.

back next

Last Revised: April 03, 2012

This content is written by the POZ and AIDSmeds editorial team. For more information, please visit our "About Us" page.

TREATMENT NEWS
Hepatitis C updates
Hep C Genotype 3 Treatment Results Same in HIV Coinfection

Waistlines Tied to Liver Stiffness in Women With Hep C

Women Spontaneously Clear Hep C Better Than Men

HIV/Hep B Coinfection Responds Very Well to Viread

Liver Cancer Deaths Double in Two Decades

Conditions Outside of AIDS Pose Significant Threat to People With HIV

HIV and Hepatitis C Coinfection Raises Cognitive Impairment Risk for Men

Hep C Protease Inhibitor Incivek Is Safe, Effective for HIV Coinfection

HIV Meds and Alcohol Not a Toxic Mix, Yet Many Skip Doses While Drinking

Multivitamins: More Not Better When HIV Meds are Being Used

Obesity Linked to Chronic Non-AIDS Health Problems in HIV+ People

HIV Therapy Helps Reduce Risk of Non-AIDS Illnesses

Sofosbuvir (GS-7977) Shows Promise in HIV/Hep C-Coinfected People

Black Women With HIV and Hep C Less Likely to Die of Liver-Related Disease

Interferon, High Blood Pressure May be Risk to Vision

CDC Officially Recommends One-Time Hep C Tests for All Baby Boomers

Despite ARV Therapy, HIV/Hep C Patients Face Increased Risk of Serious Liver Disease

Hep C Treatment Failure Can Still Mean Less Liver Inflammation

HIV/Hep C Coinfection and Each Virus by Itself Increase Hip Fracture Risk

1 in 4 Los Angeles Homeless Have Hep C

Hep B Prevalence in U.S. Is Double the CDC’s Estimate

Curative Hep C Treatment Benefits Non-Liver Health and Survival in HIV

CDC Set to Recommend One-Time Hep C Tests for All Baby Boomers

Hep C Risk Highest for Baby Boomers, but Most Haven’t Been Tested

Depression Is Common and Needs Managing Before and During Hep C Interferon Treatment

Risk of Liver-Related Deaths Twice as High With Chronic Hep B Versus Hep C

Facebook to Promote Organ Donation; May Benefit People With Hep C or HIV

FDA to Docs: Best to Avoid Victrelis With Norvir-Boosted HIV Protease Inhibitors

Revised U.S. Guidelines Make Key HIV and Hep C Treatment Recs

Clearing or Curing Acute HCV Does Not Protect Against Reinfection

HCV Testing, Diagnosis Being Overlooked in People With HIV

Marker of Active Hep B Infection Declines in Those Coinfected with HIV, Treated with Tenofovir

ARV Liver Toxicity in HIV/Hep C Coinfected Patients on the Decline

Treating HIV During Pregnancy Also Lowers Risk of Transmitting Hep C to Baby

Incivek, Victrelis Studies Hint at Superior Cure Rates in HIV/HCV Coinfection

Hep C Now Trumps HIV as Cause of Death in U.S.

Merck Warns of Victrelis and HIV Protease Inhibitor Interactions

Many at Risk for Hep B in U.S. Aren't Getting Vaccinated

Experts Issue Early Guide for Hep C Protease Inhibitor Therapy in People Living with HIV

Chronic Hep B Doubles Risk of AIDS Illnesses and Death in People Living With HIV

Victrelis Keeps Hep C Viral Load Undetectable for 24 Weeks in 7 of 10 Coinfected Patients

Despite High CD4s, Unchecked Viral Load Linked to Higher AIDS Risk

Hepatitis C Medication Adherence Is an Important Challenge, Study Shows

New Hep C Treatment Guidelines Spell Out Incivek and Victrelis Use

Hepatitis C in the U.S. May Be Underestimated by Over a Million

BMS Drug Boosts Hep C Cure Rates

Coffee Helps Minimize Hepatitis C Treatment Side Effects

HIV Linked to False Negative Hep C Results Using Some Rapid Assays

DRACO: A Broad-Spectrum Therapy Against Multiple Viruses

Doubled Risk of Death Among Publicly Insured People With HIV in U.S.

Counseling, Drug Treatment Can Increase Hep C Treatment Eligibility

WHO World Hepatitis Day Report: One in 12 Living With Chronic Hep B or C

Hepatitis C Sexually Transmitted between HIV-Positive Men

HIV, Hep C Drug Development Pipeline is 'Robust,' Says Report

Survey Finds Support for Universal Hep C Testing

Liver Damage Increases Tenofovir-Induced Kidney Impairment Risk


> More Treatment News

Search for news stories about this topic

Lesson Index
Collapse All | Up One Level

TALK TO US
Tell us what you think
Poll
Have you visited your health care provider within the last 4 months?
Yes
No


Survey
HIV and Hepatitis C

more surveys
[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.